◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

Oruka Therapeutics, Inc.

CIK: 907654 SIC: 2834
-
Revenue
$-105.43M
Net Income
-
Gross Margin
-
Op. Margin
$-153.36M
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 7 of 44 quarterly reports available
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Operating Expenses $34.43M $34.10M $28.43M $25.09M $30.32M $29.45M $3.12M
Research & Development $27.64M $28.99M $24.09M $19.93M $25.50M $25.69M $130.00K
Operating Income $-34.43M $-34.10M $-28.43M $-25.09M $-30.32M $-29.45M $-3.12M
Interest Expense - - - - - $504.00K -
Interest Income $4.85M $3.83M $3.86M $4.09M $4.53M $1.33M -
Other Income/Expense $-11.78M $3.83M $3.85M $4.09M $142.00K $826.00K -
Net Income $-29.58M $-30.28M $-24.57M $-21.00M $-25.78M $-28.62M $-2.68M
Basic EPS nan nan -0.46 -0.40 2.21 -1.46 -0.18
Diluted EPS nan nan -0.46 -0.40 2.21 -1.46 -0.18
Basic Shares Outstanding - - 42.1M 41.7M 9.0M 15.0M 14.5M
Diluted Shares Outstanding - - 42.1M 41.7M 9.0M 15.0M 14.5M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $46.94M $91.25M $65.40M $83.57M $61.58M $410.88M $33.28M
Short-term Investments $290.11M $257.90M $263.01M $265.52M $314.07M - -
Other Current Assets $6.81M $6.01M $3.61M $2.99M $1.22M $2.07M $537.00K
Total Current Assets $343.86M $355.16M $332.01M $352.08M $376.87M $412.95M $33.82M
Property Plant & Equipment $288.00K $253.00K $174.00K $159.00K $162.00K $160.00K $4.00K
Long-term Investments $142.54M $151.76M $23.05M $23.95M $18.07M - -
Other Non-current Assets $103.00K $103.00K $103.00K $103.00K $43.00K $43.00K $12.00K
Total Assets $488.62M $509.25M $357.42M $377.11M $396.02M $414.09M $33.84M
Accounts Payable - - - - - - $571.00K
Total Current Liabilities $15.37M $20.97M $12.11M $11.72M $13.04M $18.04M $1.27M
Total Liabilities $16.69M $22.46M $13.78M $12.39M $13.80M $18.88M $1.27M
Common Stock $49.00K $48.00K $37.00K $37.00K $37.00K $35.00K $14.00K
Retained Earnings $-189.16M $-159.57M $-129.30M $-104.72M $-83.72M $-57.94M $-193.43M
Total Stockholders Equity $471.93M $486.79M $343.64M $364.73M $382.22M $342.37M $32.57M
Total Liabilities & Equity $488.62M $509.25M $357.42M $377.11M $396.02M $414.09M $33.84M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $-29.58M $-30.28M $-24.57M $-21.00M $-25.78M $-28.62M $-4.69M
Depreciation & Amortization - - - - - - $6.00K
Stock-based Compensation $4.12M $20.12M $9.96M $4.88M $5.15M $9.77M $226.00K
Change in Payables - - - - - - $209.00K
Operating Cash Flow $-22.59M $-65.62M $-44.01M $-20.87M $-18.82M $-39.02M $-4.16M
Capital Expenditure $63.00K $146.00K $47.00K $13.00K $18.00K $171.00K -
Purchases of Investments $100.99M $419.97M $152.29M $44.29M - - -
Investing Cash Flow $-22.02M $-74.72M $47.73M $42.87M $-329.96M $-171.00K -
Stock Issued $562.00K $109.00K $109.00K - - - -
Financing Cash Flow $298.00K $170.02M $109.00K - $-526.00K $450.06M $14.00K
Net Change in Cash - - - - - - $-4.15M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Operating Expenses $34.10M - $87.62M -
Research & Development $28.99M - $73.00M -
Operating Income $-34.10M - $-87.62M -
Interest Expense - - - -
Interest Income $3.83M - $11.78M -
Other Income/Expense $3.83M - $11.77M -
Net Income $-30.28M $-22.24M $-75.85M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $91.25M $61.58M
Short-term Investments $257.90M $314.07M
Other Current Assets $6.01M $1.22M
Total Current Assets $355.16M $376.87M
Property Plant & Equipment $253.00K $162.00K
Long-term Investments $151.76M $18.07M
Other Non-current Assets $103.00K $43.00K
Total Assets $509.25M $396.02M
Total Current Liabilities $20.97M $13.04M
Total Liabilities $22.46M $13.80M
Common Stock $48.00K $37.00K
Retained Earnings $-159.57M $-83.72M
Total Stockholders Equity $486.79M $382.22M
Total Liabilities & Equity $509.25M $396.02M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-30.28M $-22.24M $-75.85M -
Stock-based Compensation - - $20.12M -
Operating Cash Flow - - $-65.62M -
Capital Expenditure - - $146.00K -
Purchases of Investments - - $419.97M -
Investing Cash Flow - - $-74.72M -
Stock Issued - - $109.00K -
Financing Cash Flow - - $170.02M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...